Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR plus breast cancer: A secondary analysis of the SOFT trial.

被引：0

作者：

Brown, Lauren Claire

Luen, Stephen James

Molania, Ramyar

Caramia, Franco

Savas, Peter

VanGeelen, Courtney

Chic, Nuria

Fleming, Gini F.

Kammler, Rosita

Colleoni, Marco

Viale, Giuseppe

Speed, Terence Paul

Regan, Meredith M.

Francis, Prudence A.

Loi, Sherene

机构：

[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Univ Chicago, Chicago, IL USA

[3] Int Breast Canc Study Grp, Bern, Switzerland

[4] European Inst Oncol, Milan, Italy

[5] Univ Milan, European Inst Oncol, Milan, Italy

[6] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia

[7] Dana Farber Canc Inst, Boston, MA USA

[8] Int Breast Canc Study Grp, Boston, MA USA

[9] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

504

引用

页数：1

共 50 条

[41] Cryoablation Without Excision for Low-Risk Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial
Fine, Richard E.
Gilmore, Richard C.
Dietz, Jill R.
Boolbol, Susan K.
Berry, Michael P.
Han, Linda K.
Kenler, Andrew S.
Sabel, Michael
Tomkovich, Kenneth R.
VanderWalde, Noam A.
Chen, Margaret
Columbus, Karen S.
Curcio, Lisa D.
Feldman, Sheldon M.
Gold, Linsey
Hernandez, Lydia
Manahan, Eric R.
Seedman, Susan A.
Vaidya, Rashmi P.
Sevrukov, Alexander B.
Aoun, Hussein D.
Hicks, Randy D.
Simmons, Rache M.
ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (10) : 5525 - 5534
[42] Prediction of 10yr distant recurrence (DR) using the Prosigna (PAM50) assay in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal Danish women with hormone receptor-positive (HR plus ) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET) alone.
Laenkholm, Anne-Vibeke
Jensen, Maj-Britt
Eriksen, Jens Ole
Kiboll, Torben
Rasmussen, Birgitte Bruun
Knoop, Ann S.
Ferree, Sean
Haffner, Taryn
Schaper, Carl
Ejlertsen, Bent
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[43] Cryoablation Without Excision for Low-Risk Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial
Richard E. Fine
Richard C. Gilmore
Jill R. Dietz
Susan K. Boolbol
Michael P. Berry
Linda K. Han
Andrew S. Kenler
Michael Sabel
Kenneth R. Tomkovich
Noam A. VanderWalde
Margaret Chen
Karen S. Columbus
Lisa D. Curcio
Sheldon M. Feldman
Linsey Gold
Lydia Hernandez
Eric R. Manahan
Susan A. Seedman
Rashmi P. Vaidya
Alexander B. Sevrukov
Hussein D. Aoun
Randy D. Hicks
Rache M. Simmons
Annals of Surgical Oncology, 2021, 28 : 5525 - 5534
[44] Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial.
Goss, Paul E.
Barrios, Carlos H.
Chan, Arlene
Finkelstein, Dianne M.
Iwata, Hiroji
Martin, Miguel
Braun, Ada
Ding, Beiying
Maniar, Tapan
Coleman, Robert E.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[45] Estrogen levels in premenopausal patients (pts) with hormone-receptor positive (HR plus ) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy final analysis
Bellet, M.
Gray, K.
Francis, P.
Lang, I.
Ciruelos, E.
Lluch, A.
Climent, M. Angel
Catalan, G.
Avella, A.
Bohn, U.
Gonzalez-Martin, A.
Zaman, K.
Ferrer, R.
Azaro, A.
Rajasekaran, A.
De la Pena, L.
Fleming, G.
Regan, M. M.
CANCER RESEARCH, 2019, 79 (04)
[46] Comment on: Cryoablation Without Excision for Low-Risk Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial
E. M. F. van de Voort
M. Franckena
G. M. Struik
A. Moelker
T. M. A. L. Klem
Annals of Surgical Oncology, 2023, 30 : 3284 - 3285
[47] Comment on: Cryoablation Without Excision for Low-Risk Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial
van de Voort, E. M. F.
Franckena, M.
Struik, G. M.
Moelker, A.
Klem, T. M. A. L.
ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (06) : 3284 - 3285
[48] Germline Mutation Status and Therapy Response in High-Risk Early-Stage Breast Cancer: a Secondary Analysis of the Geparocto Randomized Clinical Trial (NCT02125344)
Pohl-Rescigno, Esther
Hauke, Jan
Rhiem, Kerstin
Moebus, Volker
Furlanetto, Jenny
Denkert, Carsten
Fasching, Peter A.
Hanusch, Claus
Tesch, Hans
Weber-Lassalle, Nana
Mueller, Volkmar
Untch, Michael
Luebbe, Kristina
Lederer, Bianca
Jackisch, Christian
Nekljudova, Valentina
Schmutzler, Rita K.
Loibl, Sibylle
Schneeweiss, Andreas
Hahnen, Eric
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 7 - 8
[49] Homologous recombination deficiency predicts response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: Secondary analysis of the neocart randomized clinical trial.
Zhang, Liulu
Wu, Zhiyong
Li, Jie
Lin, Ying
Liu, Zhenzhen
Cao, Yin
Zhang, Gangling
Zhang, Yi
Chen, Yuanqi
Gao, Hong-Fei
Yang, Mei
Yang, Ciqiu
Zhu, Teng
Cheng, Min-Yi
Ji, Fei
Li, Jieqing
Wang, Kun
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[50] Validation of prediction of distant recurrence (DR) by Prosigna (PAM50) in subgroups of a Danish Breast Cancer Cooperative Group (DBCG) cohort of node-positive (N1), hormone receptor positive (HR plus ), postmenopausal early breast cancer (EBC) patients allocated 5yr of endocrine therapy (ET).
Ejlertsen, Bent
Jensen, Maj-Britt
Eriksen, Jens Ole
Kiboll, Torben
Rasmussen, Birgitte Bruun
Knoop, Ann S.
Ferree, Sean
Haffner, Taryn
Schaper, Carl
Laenkholm, Anne-Vibeke
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →